Research progress of PD-1 antibody therapy and related biomarkers in biliary tract cancers

VernacularTitle:胆道癌程序性死亡蛋白-1抗体治疗及相关生物标志物研究进展
Author: Chenghao CUI ¹ ; Yurong LIANG
Author Information

1. 解放军总医院肝胆胰外科医学部　解放军总医院肝胆外科研究所　全军肝胆外科重点实验室，北京　100853
Keywords: Biliary tract neoplasms; Immunotherapy; Programmed death-1 antibody; Biomarkers
From: Chinese Journal of Hepatobiliary Surgery 2021;27(9):712-717
CountryChina
Language:Chinese
Abstract: Biliary tract cancer is characterized by high heterogeneous, rare and refractory malignancy. Since patients are often diagnosed at late stage, the radical resection rate is low, and the effect of traditional adjuvant therapy is limited, therefore the prognosis of patients is poor. Recently Immunotherapy has opened up a new field for tumor therapy. Porgrammed death-1 (PD-1) antibody therapy has a great clinical application prospects. The efficacy of related therapies in biliary tract tumors is being evaluated under a number of clinical trials. One of the main challenges is to identify the biomarkers that can predict the response and prognosis of PD-1 antibody therapy. This article aims to summarize the research progress of PD-1 antibody therapy and related biomarkers such as PD-L1, tumor mutational burden, DNA damage repair in biliary tract cancers, and to prospect the future research direction.